398 related articles for article (PubMed ID: 23708506)
1. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Zhang J; Jiang D; Li X; Lv J; Xie L; Zheng L; Gavine PR; Hu Q; Shi Y; Tan L; Ge D; Xu S; Li L; Zhu L; Hou Y; Wang Q
Lab Invest; 2014 Aug; 94(8):917-26. PubMed ID: 24999713
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
6. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
7. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice.
Tian F; Zhang C; Tian W; Jiang Y; Zhang X
Oncol Rep; 2012 Jul; 28(1):232-40. PubMed ID: 22552693
[TBL] [Abstract][Full Text] [Related]
11. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Saito S; Morishima K; Ui T; Hoshino H; Matsubara D; Ishikawa S; Aburatani H; Fukayama M; Hosoya Y; Sata N; Lefor AK; Yasuda Y; Niki T
BMC Cancer; 2015 Feb; 15():82. PubMed ID: 25884729
[TBL] [Abstract][Full Text] [Related]
12. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
13. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Tian F; Fan T; Zhang Y; Jiang Y; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):847-55. PubMed ID: 23017833
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
Guo XF; Li SS; Zhu XF; Dou QH; Liu D
Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
[TBL] [Abstract][Full Text] [Related]
15. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
[TBL] [Abstract][Full Text] [Related]
16. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
Cui G; Cui M; Li Y; Liang Y; Li W; Guo H; Zhao S
Med Oncol; 2015 Apr; 32(4):124. PubMed ID: 25788032
[TBL] [Abstract][Full Text] [Related]
18. Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Li J; Li B; Xu WW; Chan KW; Guan XY; Qin YR; Lee NP; Chan KT; Law S; Tsao SW; Cheung AL
Expert Opin Ther Targets; 2016; 20(1):7-18. PubMed ID: 26568207
[TBL] [Abstract][Full Text] [Related]
19. The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
Ako E; Yamashita Y; Ohira M; Yamazaki M; Hori T; Kubo N; Sawada T; Hirakawa K
Oncol Rep; 2007 Apr; 17(4):887-93. PubMed ID: 17342332
[TBL] [Abstract][Full Text] [Related]
20. Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
Ma W; Zhang T; Pan J; Shi N; Fan Q; Wang L; Lu SH
Oncol Rep; 2014 Oct; 32(4):1601-9. PubMed ID: 25175038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
